Literature DB >> 12552254

Pathogenetic aspects of immune deficiency associated with beta-thalassemia.

Dimitrios Farmakis1, Anastasios Giakoumis, Evaggelos Polymeropoulos, Athanasios Aessopos.   

Abstract

Infectious complications constitute the second most common cause of mortality and a main cause of morbidity in beta-thalassemia. Besides the high risk of blood-borne infections associated with multiple transfusions, the increased susceptibility of these patients to infectious diseases has been attributed to a coexistent immune deficiency. Immune abnormalities have also been held responsible for the frequent occurrence of malignancies in beta-thalassemia, especially leukemia and lymphomas. Recent studies on immune competence in beta-thalassemia have revealed numerous quantitative and functional defects, involving T and B lymphocytes, immunoglobulin production, neutrophils and macrophages, chemotaxis, and phagocytosis, as well as the complement system. Regarding pathogenesis, iron overload, a primary complication of both thalassemia itself and transfusion therapy, is thought to be the main precipitating mechanism, due to the important immunoregulatory properties of iron and its binding proteins; iron excess may derange the immune balance in favor of the growth of infectious organisms. Other factors include multiple transfusions, associated with constant allo-antigenic stimulation, as well as with transmission of immunosuppressive viruses; splenectomy, resulting in increased susceptibility to infections by encapsulated bacteria and to immune system modifications; low levels of zinc, another immune regulator; iron chelation therapy, which predisposes to serious infections by yersinia species; and the circulation of abnormal native thalassemic erythrocytes, forming another permanent immune stimulus. Thus surveillance for infections in patients with beta-thalassemia is crucial, while further studies are warranted on immune function abnormalities and the implicated mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552254

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  27 in total

1.  Prevalence of anti-HAV antibodies in multitransfused patients with beta-thalassemia.

Authors:  Dimitrios Siagris; Alexandra Kouraklis-Symeonidis; Irini Konstantinidou; Myrto Christofidou; Ioannis Starakis; Alexandra Lekkou; Christos Papadimitriou; Alexandros Blikas; Nicholas Zoumbos; Chryssoula Labropoulou-Karatza
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

2.  Characterization of circulating CD4+ CD8+ double positive and CD4- CD8- double negative T-lymphocyte in children with β-thalassemia major.

Authors:  Asmaa M Zahran; Khaled Saad; Khalid I Elsayh; Mohamd A Alblihed
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

3.  Leukocytes apoptosis and adipocytokines in children with beta thalassemia major.

Authors:  Khalid I Elsayh; Wafaa S Mohammed; Asmaa M Zahran; Khaled Saad
Journal:  Clin Exp Med       Date:  2015-06-09       Impact factor: 3.984

4.  Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia.

Authors:  Brigitta Buttari; Elisabetta Profumo; Patrizia Caprari; Sara Massimi; Francesco Sorrentino; Laura Maffei; Marco Gabbianelli; Rachele Riganò
Journal:  Ann Hematol       Date:  2020-08-15       Impact factor: 3.673

5.  Co-Incidence or Co-Existence? Acute Lymphoblastic Leukaemia in HbE-alpha Thalassaemia: A Case Report with Review of Literature.

Authors:  Rithika Rajendran; Febe Renjitha Suman; Aruna Rajendran; Julius Xavier Scott
Journal:  J Clin Diagn Res       Date:  2015-11-01

6.  Alteration of T Cell Subtypes in Beta-Thalassaemia Major: Impact of Ferritin Level.

Authors:  Batoul Pourgheysari; Leila Karimi; Pezhman Beshkar
Journal:  J Clin Diagn Res       Date:  2016-02-01

7.  Low IL-2 Expressing T Cells in Thalassemia Major Patients: Is It Immune Aging.

Authors:  Batoul Pourgheysari; Leila Karimi; Raihaneh Bagheri; Soleiman Kheiri
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-07       Impact factor: 0.900

8.  Serum immunoglobulin levels in splenectomized and non- splenectomized patients with major Beta-thalassemia.

Authors:  Mojgan Kiani-Amin; Mohammadmehdi Daneshi; Parviz Ayazi; Shima Mohammadian; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2011-03       Impact factor: 0.364

9.  Study on Efficacy of Hepatitis B Immunization in Vaccinated Beta-thalassemia Children in Tehran.

Authors:  Zohreh Sharifi; Saeideh Milani; Mahmood Mahmoodian Shooshtari
Journal:  Iran J Pediatr       Date:  2010-06       Impact factor: 0.364

10.  Cardiac function and iron chelation in thalassemia major and intermedia: a review of the underlying pathophysiology and approach to chelation management.

Authors:  Athanasios Aessopos; Vasilios Berdoukas
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-18       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.